

**This communication should be viewed by:**

Primary Care Providers  
Behavioral Health Providers  
Clinical staff  
Specialist  
Claims and Billing Department  
Facility/Practice staff

## Pharmaceutical Policy Updates Effective December 1, 2024

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at [mvphealthcare.com](https://mvphealthcare.com) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective December 1, 2024, and will be available for viewing on or before November 1, 2024. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Risankizumab (Skyrizi) Part B	Updated
Ustekinumab Part B	Reviewed/No Changes
Hemophilia Gene Therapy Part B	Updated
Enteral Therapy Part B	Reviewed/No Changes
C. Difficile Drug Therapy Part B	Updated
Infliximab Part B	Updated

To view all communications, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

